Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Perioperative chemoimmunotherapy demonstrated significant long-term survival benefits for patients with resectable non-small-cell lung cancer (NSCLC). The NADIM trial reported 5-year survival rates of 65% progression-free and 69% overall, with a manageable safety profile.
Area Of Science
- Oncology
- Immunotherapy
- Clinical Trials
Background
- Perioperative immunotherapy has shown short-term efficacy in resectable non-small-cell lung cancer (NSCLC).
- The NADIM trial aimed to evaluate the long-term survival outcomes of this treatment approach.
Purpose Of The Study
- To report the 5-year survival data from the NADIM phase 2 trial.
- To assess the long-term efficacy and safety of perioperative chemoimmunotherapy in resectable stage IIIA NSCLC.
Main Methods
- A multicentre, single-arm, phase 2 trial involving 46 patients with resectable stage IIIA NSCLC.
- Neoadjuvant treatment: paclitaxel, carboplatin, and nivolumab, followed by surgery.
- Adjuvant treatment: 1 year of nivolumab monotherapy.
Main Results
- 5-year progression-free survival was 65.0% and overall survival was 69.3%.
- 14 patients (30%) died, with 9 (20%) from disease relapse and 5 (11%) from non-tumour-related causes.
- Grade 3 or worse treatment-related adverse events occurred in 30% during neoadjuvant and 19% during adjuvant treatment, with no unexpected long-term toxicities.
Conclusions
- Perioperative chemoimmunotherapy offers promising long-term benefits for resectable stage IIIA NSCLC.
- The treatment demonstrated a favorable safety profile, supporting its continued use in this patient population.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...